Çelik Mehmet Semih, Aktaş Hamza
University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital, Department of Dermatology, Diyarbakir, Turkey.
Ir J Med Sci. 2025 Jun 2. doi: 10.1007/s11845-025-03969-6.
IL-17 and IL-23 inhibitors are widely used as biological agents in patients with psoriasis vulgaris to suppress inflammation and reduce disease severity. This study aimed to examine changes in inflammatory parameters, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic inflammation index (SII), platelet/hemoglobin ratio (PHR), and red cell distribution width/platelet ratio (RPR), as well as the Psoriasis Area and Severity Index (PASI), in psoriasis patients receiving biological therapy (IL-17 and IL-23 inhibitors).
This retrospective study included 110 patients with psoriasis vulgaris treated with IL-23 (risankizumab, guselkumab or IL-17 inhibitors ( secukinumab, and ixekizumab). Disease severity was assessed using the PASI score. Hematological parameters (NLR, PLR, SII, PHR, and RPR) and PASI values of the patients were recorded and analyzed at baseline (month 0) and during treatment (month 6).
A significant decrease was observed in NLR, SII, and PHR values during treatment. NLR decreased significantly from 2.43 ± 1.25 at baseline to 2.12 ± 0.81 at month 6 (p = 0.002). Both IL-17 and IL-23 groups significantly reduced NLR (p = 0.044, p = 0.029, respectively). SII decreased significantly from 695 ± 390 at baseline to 588 ± 288 at month 6 (p = 0.002). Both groups significantly reduced SII levels (p = 0.044, p = 0.018, respectively).PHR decreased significantly from 19.8 ± 6.60 at baseline to 19.2 ± 6.58 at month 6 (p = 0.033).PASI score significantly decreased during treatment (p < 0.001).
The significant reduction in NLR and SII levels in both the IL-17 and IL-23 groups suggests that these markers may be used together rather than separately in treatment follow-up. The significant decrease in PHR levels may indicate that IL-17 and IL-23 inhibitors contribute to reducing cardiovascular disease risk in patients with psoriasis vulgaris and promote a favorable long-term prognosis.
白细胞介素-17（IL-17）和白细胞介素-23（IL-23）抑制剂作为生物制剂广泛应用于寻常型银屑病患者，以抑制炎症并减轻疾病严重程度。本研究旨在检测接受生物治疗（IL-17和IL-23抑制剂）的银屑病患者炎症参数的变化，包括中性粒细胞/淋巴细胞比值（NLR）、血小板/淋巴细胞比值（PLR）、全身炎症指数（SII）、血小板/血红蛋白比值（PHR）和红细胞分布宽度/血小板比值（RPR），以及银屑病面积和严重程度指数（PASI）。
本回顾性研究纳入了110例接受IL-23（瑞莎珠单抗、古塞库单抗）或IL-17抑制剂（司库奇尤单抗、依奇珠单抗）治疗的寻常型银屑病患者。使用PASI评分评估疾病严重程度。记录并分析患者在基线（第0个月）和治疗期间（第6个月）的血液学参数（NLR、PLR、SII、PHR和RPR）及PASI值。
治疗期间观察到NLR、SII和PHR值显著降低。NLR从基线时的2.43±1.25显著降至第6个月时的2.12±0.81（p = 0.002）。IL-17和IL-23两组均显著降低了NLR（分别为p = 0.044和p = 0.029）。SII从基线时的695±390显著降至第6个月时的588±288（p = 0.002）。两组均显著降低了SII水平（分别为p = 0.044和p = 0.018）。PHR从基线时的19.8±6.60显著降至第6个月时的19.2±6.58（p = 0.033）。PASI评分在治疗期间显著降低（p < 0.001）。
IL-17和IL-23两组中NLR和SII水平的显著降低表明这些指标在治疗随访中可联合使用而非单独使用。PHR水平的显著降低可能表明IL-17和IL-23抑制剂有助于降低寻常型银屑病患者的心血管疾病风险，并促进良好的长期预后。
